Firas Rahhal, MD
Ophthalmology · Los Angeles, CANPI 1881658615
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $231,232 of the $263,815 with a category attached, or 87.6%. 28 manufacturers reported payments, led by Beaver-visitec International, Inc. at 42.6% of the total. 2025 is the largest year on record at $117,059, more than ten times the $7,688 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $1142.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beaver-visitec International, Inc.$112K
- Alcon$88K
- Alcon Research LLC$18K
- Coherus Oncology, Inc.$16K
- Boehringer Ingelheim$15K
- Astellas Pharma US Inc$3K
- plus $11K from 22 others
Across 163 payments — averaging $5980.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$541K
- Kyowa Kirin, Inc.$274K
- Regeneron$66K
- Alcon Research LLC$63K
- Boehringer Ingelheim$25K
- AbbVie$3K
- plus $3K from 2 others
What the payments were for
- Consulting fees$231,23288%
- Speaking & faculty fees$15,8006%
- Travel & lodging$6,3862%
- Food & beverage$10,1884%
- Education$930%
- Gifts$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beaver-visitec International, Inc. | 7 | $112,358 |
| Alcon | 65 | $88,289 |
| Alcon Research LLC | 8 | $18,147 |
| Coherus Oncology, Inc. | 10 | $15,723 |
| Boehringer Ingelheim | 10 | $15,459 |
| Astellas Pharma US Inc | 5 | $3,198 |
| Carl Zeiss Meditec, Inc. | 3 | $2,836 |
| Roche TCRC, Inc. | 3 | $1,848 |
| Apellis Pharmaceuticals, Inc. | 17 | $1,011 |
| AbbVie(2 entities) | 32 | $840 |
| Alimera Sciences, Inc. | 4 | $775 |
| Genentech USA, Inc. | 20 | $518 |
| Regeneron Healthcare Solutions, Inc. | 13 | $514 |
| Sandoz | 3 | $281 |
| Eyepoint US, Inc. | 3 | $272 |
| Kyowa Kirin, Inc. | 4 | $266 |
| Amgen | 3 | $266 |
| Ocular Therapeutix, Inc. | 4 | $216 |
| Mallinckrodt Hospital Products Inc. | 5 | $198 |
| Regeneron | 2 | $183 |
| Bausch & Lomb Americas Inc. | 1 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $125 |
| Novartis | 1 | $102 |
| Genentech, Inc. | 1 | $77 |
| Biogen | 3 | $66 |
| Baxter Healthcare | 1 | $58 |
| Oculus Surgical Inc. | 1 | $23 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$51,945
- Unity$21,531
- Cimerli$15,596
- ARGOS$7,000
- Systane$7,000
- LenSx$7,000
- Hydrus Microstent$7,000
- ILUX$7,000
- Izervay$3,054
- Non-Covered Product$1,848
- NGENUITY$1,546
- FINESSE SHARKSKIN$956
- Iluvien$750
- Syfovre$412
- Alcon Greishaber Finesse$345
- EYLEA$133
- STELLARIS PC$125
- DEXYCU$125
- YUTIQ$123
- BEOVU$102
How this compares
$263,815 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 31 | $21,022 |
| ProlensaBromfenac Sodium | 39 | $20,372 |
| LumiganBimatoprost | 51 | $19,851 |
| Brimonidine Tartrate | 269 | $14,516 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $13,289 |
| XiidraLifitegrast | 12 | $11,317 |
| Prednisolone Acetate | 242 | $11,185 |
| Alphagan PBrimonidine Tartrate | 22 | $7,094 |
| MoxifloxacinMoxifloxacin Hcl | 319 | $6,317 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $5,646 |
| Bromfenac Sodium | 28 | $5,096 |
| RhopressaNetarsudil Mesylate | 15 | $4,686 |
| VyzultaLatanoprostene Bunod | 18 | $4,294 |
| Cyclosporine | 15 | $3,905 |
| Travoprost | 28 | $3,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $840 | $61,256151 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $125 | $20,37239 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $150 | $15,61030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
- Amy JainLos Angeles$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.